Annex 1, the European Union’s revised GMP requirements for the manufacturing of sterile medicinal products, will take effect on 25 August 2023. In this panel, experts involved in industry’s commenting of the draft versions of Annex 1 offered background information on how the document was developed and answered questions on its implementation.
Opening the 2023 ISPE Europe Annual Conference on 8 May, Peter Twomey, Head of Inspections for the European Medicines Agency (EMA), offered a keynote address titled International Cooperation, Harmonization, and Reliance in GMP.
Emer Cooke, Executive Director of the European Medicines Agency (EMA), delivered an impactful keynote address at the 2023 ISPE Europe Annual Conference, held 8-10 May , in Amsterdam, The Netherlands. Cooke...
As we are all aware, the COVID-19 pandemic has had a unique, world-wide effect on the pharmaceutical industry as well as health authorities. At the height of the pandemic, and continuing as it appears to wane, health authorities have not been able not carry out normal, in-person inspections of pharmaceutical manufacturing sites. However, in the ”Age of Covid,” using the Internet and associated...
That question was at the heart of the of ISPE’s “Expert Xchange: Regulatory Summit on ICH Q9 Revision” held 9 June 2022. Seventy-one participants from 14 countries discussed ICH Q9(R1) and received valuable insight from several members of the Expert Working Group (EWG) assembled in 2020 to lead the ICH Q9 revision process. Discussion centered on the current state of application of quality risk...
